Dyax ups shares for planned offering - Boston Business Journal:
Dwayne Jenkings  |  by www.bizjournals.com. All rights reserved. 10.07 | 15:39

in Seattle, Wash., a biotechnology company focused on oncology and inflammation. The company, which employs more than 160 people and doesn't generate significant revenue yet, is perhaps best known for lead compound DX-88, a drug that has complete at least one late-stage human clinical trial to treat hereditary angioedema.

Contact the Editor Need Assistance? More Latest News Subscribe or renew online Hot spots for small business Our study finds the top markets for small business 10 best markets for small business 10 worst markets for small business Market leaders in select small business stats How would you start a small business? Dyax aims at $39M from stock sale Ancora anchors drug plans with $2.

2M in VC Dyax ups shares for planned offering Visits by drug sales reps have powerful impact on doctors in Seattle, Wash., a biotechnology company focused on oncology and inflammation.

Read more on by www.bizjournals.com. All rights reserved.
Post comments
Name
Place
3 + 8 =
Comments